Cel-Sci

Cel-Sci is a company that develops biotechnology immunotherapy products for the treatment of cancer and other infectious diseases. The company was founded in 1983 by Maximilian de Clara, in Vienna, Virginia, United States.

The company looks to deal with clinical phases of head and neck cancer. Their theory is to boost the immune system before turning to options such as surgery, radiation, and chemotherapy.

COVID-19

The company has began developing an immunotherapy solution for the potential to treat patients with COVID-19. The outbreak of the coronavirus has prompted Cel-Sci to provide their peptide technology LEAPS which stimulates protective cell mediated T-cell responses and reduce viral loads. The technology can be used to build peptides that exhibit both antiviral and anti-inflammatory properties. LEAPS is designed to target the infectious virus, and also start the appropriate protective response to it.

LEAPS is a peptide-based medicine that can help reduce tissue damage caused by lung infections, which is a mortality issue for elderly patients.